Osaic Holdings’s Cyclo Therapeutics, Inc. Common Stock CYTH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q1
– Sell
-67
Closed -$39 – 7792
2024
Q4
$39 Hold
67
– – ﹤0.01% 7307
2024
Q3
$52 Hold
67
– – ﹤0.01% 7296
2024
Q2
$85 Hold
67
– – ﹤0.01% 7262
2024
Q1
$93 Sell
67
-533
-89% -$881 ﹤0.01% 7044
2023
Q4
$954 Hold
600
– – ﹤0.01% 6770
2023
Q3
$852 Sell
600
-4,000
-87% -$6.15K ﹤0.01% 6869
2023
Q2
$7.31K Buy
4,600
+4,000
+667% +$5.11K ﹤0.01% 6130
2023
Q1
$504 Hold
600
– – ﹤0.01% 7129
2022
Q4
$1K Hold
600
– – ﹤0.01% 7003
2022
Q3
$1K Buy
+600
New +$1.26K ﹤0.01% 7111
2022
Q1
– Sell
-900
Closed -$3K – 7562
2021
Q4
$3K Buy
+900
New +$5.1K ﹤0.01% 6929

Osaic Holdings's CYTH Position: Q1 2025 in Review

Osaic Holdings sold out of Cyclo Therapeutics, Inc. Common Stock (CYTH) in Q1 2025, closing a stake of 67 shares — an estimated $39 sold.

Osaic Holdings first reported a position in CYTH in Q4 2021 and held it in 11 quarters. The position peaked at $7.31K in Q2 2023. 0 funds tracked by Wall St. Rank hold CYTH as of Q1 2025.

  • Osaic Holdings reported no remaining Cyclo Therapeutics, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
  • Osaic Holdings sold 67 Cyclo Therapeutics, Inc. Common Stock shares in Q1 2025, an estimated $39.
  • Osaic Holdings first reported a position in Cyclo Therapeutics, Inc. Common Stock in Q4 2021 and held it in 11 quarters.
  • Osaic Holdings's Cyclo Therapeutics, Inc. Common Stock position peaked at $7.31K in Q2 2023.
  • 0 funds tracked by Wall St. Rank held Cyclo Therapeutics, Inc. Common Stock as of Q1 2025.

Based on Osaic Holdings's 13F filing for Q1 2025, filed 12 May 2025.